Positron Emission Tomography Scanning for Recurrent Bladder Cancer

James M Wilson; Robert A Huddart

doi:10.1016/j.euf.2016.02.002

Positron Emission Tomography Scanning for Recurrent Bladder Cancer

Eur Urol Focus. 2016 Jun;2(2):219-220. doi: 10.1016/j.euf.2016.02.002. Epub 2016 Mar 19.

Authors

James M Wilson¹, Robert A Huddart²

Affiliations

¹ The Royal Marsden Hospital, Sutton, Surrey, UK; The Institute of Cancer Research, Sutton, London, UK. Electronic address: james.wilson@rmh.nhs.uk.
² The Royal Marsden Hospital, Sutton, Surrey, UK; The Institute of Cancer Research, Sutton, London, UK.

PMID: 28723538
DOI: 10.1016/j.euf.2016.02.002

Abstract

The benefit of ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) over CT in detecting distant relapse is uncertain. A means of reducing bladder activity is necessary for useful imaging of bladder wall and pelvic lymph node recurrences with FDG-PET/CT.